[go: up one dir, main page]

MX2008000087A - Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5. - Google Patents

Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.

Info

Publication number
MX2008000087A
MX2008000087A MX2008000087A MX2008000087A MX2008000087A MX 2008000087 A MX2008000087 A MX 2008000087A MX 2008000087 A MX2008000087 A MX 2008000087A MX 2008000087 A MX2008000087 A MX 2008000087A MX 2008000087 A MX2008000087 A MX 2008000087A
Authority
MX
Mexico
Prior art keywords
formulations
pde5
pde5 inhibitor
oral
oral formulations
Prior art date
Application number
MX2008000087A
Other languages
English (en)
Inventor
David Monteith
Pascal Borderies
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2008000087A publication Critical patent/MX2008000087A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion incluye formulaciones orales de un inhibidor de PDE5 las cuales proveen la desintegracion rapida despues de la introduccion a la cavidad oral, seguido por absorcion bucal y/o sublingual; las formulaciones que se desintegran oralmente pueden estar en una variedad de formas de dosis incluyendo tira lingual, tira sublingual, rocio oral, tableta de desintegracion rapida, oblea liofilizada, particulas granuladas y goma; las formulaciones pueden incluir un componente de liberacion extendida que permite que el inhibidor de PEDE5 sea ingerido para absorcion gastrointestinal; tambien se describen las terapias de combinacion con un segundo agente farmaceutico que se sabe que ocasiona una condicion tratable por PDE5 como un efecto lateral, tal como disfuncion erectil; el inhibidor de PDE5 de la siguiente estructura quimica es particularmente favorecido para estas formulaciones: (ver formula).
MX2008000087A 2005-06-23 2006-06-22 Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5. MX2008000087A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69321905P 2005-06-23 2005-06-23
PCT/US2006/024040 WO2007002125A1 (en) 2005-06-23 2006-06-22 Rapidly absorbing oral formulations of pde5 inhibitors

Publications (1)

Publication Number Publication Date
MX2008000087A true MX2008000087A (es) 2008-03-18

Family

ID=36997669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008000087A MX2008000087A (es) 2005-06-23 2006-06-22 Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.

Country Status (6)

Country Link
US (2) US20070031349A1 (es)
EP (1) EP1898879A1 (es)
JP (1) JP2008546786A (es)
CA (1) CA2612917A1 (es)
MX (1) MX2008000087A (es)
WO (1) WO2007002125A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2007039075A2 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
EP1905429A1 (en) * 2006-09-18 2008-04-02 Cephalon France Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors
CN102988318A (zh) * 2008-11-25 2013-03-27 田边三菱制药株式会社 口腔速崩片及其制备方法
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EP2198857A1 (en) 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
MX2011012078A (es) * 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Formulacion terapeutica bucal y/o sublingual.
JP5587671B2 (ja) * 2009-06-02 2014-09-10 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤と反鼻とを含有する医薬組成物
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
JP5704853B2 (ja) * 2009-07-27 2015-04-22 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤とジャショウシを含有する医薬組成物
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
AU2011264941B2 (en) * 2010-06-07 2014-10-16 Suda Ltd Oral spray formulations and methods for administration of sildenafil
JP2012031164A (ja) * 2010-07-06 2012-02-16 Teika Seiyaku Kk フィルム状製剤
EP2591773A4 (en) * 2010-07-06 2014-11-26 Navipharm Co Ltd TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
JP5885972B2 (ja) * 2010-09-10 2016-03-16 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2013085904A1 (en) * 2011-12-05 2013-06-13 Novadel Pharma, Inc. Oral spray formulations and methods for administration of sildenafil
KR101960100B1 (ko) * 2011-12-08 2019-03-19 에스케이케미칼 주식회사 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
AU2012379005B2 (en) 2012-05-02 2017-12-21 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
WO2014027981A2 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2014027980A1 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
US20150231092A1 (en) * 2012-08-17 2015-08-20 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
WO2014027975A2 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
NZ706302A (en) * 2012-10-11 2017-07-28 Ix Biopharma Ltd Sublingual wafer solid dosage form containing amylopectin
ES2475942B1 (es) * 2013-01-11 2015-04-16 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
WO2015070049A1 (en) * 2013-11-08 2015-05-14 Insys Pharma, Inc. Sildenafil sublingual spray formulation
US10555927B2 (en) 2013-11-11 2020-02-11 Ilysm, LLC Compositions and methods for enhancing sexual pleasure and performance
US10064905B1 (en) 2013-11-11 2018-09-04 Ilysm, LLC Pharmaceutical preparation
US20160317542A1 (en) * 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
IL276030B (en) * 2014-02-07 2022-09-01 Sentar Pharmaceuticals Inc Non-toxic systems, from natural materials, for administering medicine under the tongue
KR101484481B1 (ko) * 2014-08-07 2015-01-20 주식회사 다림바이오텍 Pde-5 저해제를 포함하는 설하분무제의 제조방법 및 이에 의하여 제조된 설하분무용 조성물
CN105055336A (zh) * 2015-09-24 2015-11-18 青岛华之草医药科技有限公司 一种治疗泌尿外科疾病的枸橼酸西地那非组合物颗粒剂
CN105663065A (zh) * 2016-04-01 2016-06-15 曾岚 一种含疏水性活性物质的冻干舌下片剂及其制备方法
WO2017201071A1 (en) * 2016-05-16 2017-11-23 Foster Howell Combination therapy for male sexual dysfunction
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
MX2020005890A (es) * 2017-12-20 2020-10-19 Klaria Pharma Holding Ab Formulacion de pelicula que comprende vardenafil, metodo para su preparacion y uso de la misma.
US10973760B1 (en) 2020-07-21 2021-04-13 King Abdulaziz University Instantly dissolving buccal films
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103634A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000054777A1 (en) * 1999-03-16 2000-09-21 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
FR2823668B1 (fr) * 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
PE20040538A1 (es) * 2002-05-31 2004-08-30 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US20050036954A1 (en) * 2003-08-12 2005-02-17 Arthur Zuckerman Combination of toothpaste, a chemical agent and natural herbs for improving sexual performance
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2008546786A (ja) 2008-12-25
EP1898879A1 (en) 2008-03-19
US20070031349A1 (en) 2007-02-08
CA2612917A1 (en) 2007-01-04
US20070122355A1 (en) 2007-05-31
WO2007002125A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
MX2008000087A (es) Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
WO2011030351A3 (en) Taste - masked pharmaceutical compositions
UA108360C2 (uk) Тверда фармацевтична композиція кортикостероїду, що розпадається у ротовій порожнині
WO2007104575A3 (en) Stable lozenge compositions providing rapid release of nicotine
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
NZ582458A (en) Orally disintegrating tablet compositions of lamotrigine
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
TW200633730A (en) Oral disintegrating dosage forms
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
WO2008052033A3 (en) Ibuprofen composition
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2007146805A3 (en) Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
MX2009010989A (es) Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.
MX339470B (es) Formulacion que contiene nicotina.
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
TW200600098A (en) Solid orally ingestible formulations of tetrodotoxin
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide